Beta-Thalassemia Market Size is expected to increase at a CAGR of 16.3% during the Study Period (2017-2030) in the 6MM – Industry Analysis, Drugs and Companies | Delveinsight

Beta-Thalassemia Market Size is expected to increase at a CAGR of 16.3% during the Study Period (2017-2030) in the 6MM - Industry Analysis, Drugs and Companies | Delveinsight

“Beta-Thalassemia Market”

DelveInsight’s Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta Thalassemia key companies, emerging pipeline therapies, Beta-Thalassemia market share occupied by individual therapies, current and forecasted Beta-thal market share in the 6MM (the US, and EU5 (the UK, Germany, France, Italy, and Spain) for the study period.

The report highlights the drivers and constraints shaping the present Beta-Thalassemia Market along with the unmet medical needs that offer opportunities to the key players to explore the underlying potential of the market.


Some of the key highlights from the Beta-Thalassemia Market Report: 

  • According to analysts at Delveinsight, among EU5 countries, Italy had the highest market size with USD 77.6 million in 2017
  • Spain had the lowest market size of Beta Thalassemia with USD 2.2 million in 2017
  • The total prevalent population of Beta-thalassemia in 6MM was 14,191 in 2017.
  • The total prevalent cases for Beta-thalassemia were highest in Italy, followed by the United States and Germany.
  • Endocrine complications and Osteoporosis was found in majority of patients with Beta Thalassemia. As per DelveInsight’s estimates, the trend would remain the same during the forecast period (2020-2030)
  • The United States accounts for the largest market size of Beta Thalassemia, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain).



Get more comprehensive insights into how Beta-Thalassemia epidemiological trends are impacting current and forecasted Beta-Thalassemia market @ Beta-Thalassemia Epidemiology Analysis and Forecast


Beta-Thalassemia Marketed Therapies 

  • Desferal: Novartis
  • Exjade: Novartis
  • Ferrirpox (deferiprone): Apotex
  • ACE-536: Acceleron Pharma/Celgene Corporation


Do you want to know how much market share the marketed therapies are going to capture by 2030? Contact @ Beta-Thalassemia Marketed Therapies and Treatment Approaches and get a comprehensive understanding of the Beta-Thalassemia therapeutic outlook


Beta Thalassemia is a genetic disorder which is inherited in an autosomal, recessive fashion. The clinical manifestations seen in patients are severe anaemia, abnormal haemoglobin and buildup of iron in the body. Being a genetic disorder, there is no specific treatment for Beta Thalassemia and the treatment regimen mainly focus on delaying progression of the disease and relieving the symptoms.

Novartis developed Exjade (Deferasirox), which is an oral iron chelator approved by the US FDA in 2005. It is a member of a new class of tridentate iron chelators, the N-substituted bis-hydroxyphenyl-triazoles. Metabolism and elimination of deferasirox are primarily by glucuronidation followed by hepatobiliary excretion into the faeces. Approved in more than 70 countries including the US and Europe, Exjade is the first once-daily oral iron chelator approved for use in patients with chronic transfusional iron overload who have a wide range of underlying anaemias.


Visit to know more about the indication, treatment algorithms in different geographies and patient journey contact to receive sample @ Beta-Thalassemia Signs, Symptoms, Diagnosis and Treatment 


Some of the key companies working on Beta-Thalassemia are:

  • BlueBird Bio
  • Protagonist Therapeutics
  • Acceleron Pharma/Celgene Corporation
  • Agios Pharmaceuticals
  • Ionis Pharmaceuticals
  • Vifor Pharma
  • Orchard Therapeutics
  • Sangamo Therapeutics/Sanofi
  • CRISPR Therapeutics/Vertex Pharmaceuticals
  • DisperSol Technologies
  • Kiadis
  • Incyte Corporation/Novartis
  • Editas Medicine
  • Global Blood Therapeutics/Syros Pharmaceuticals
  • And Many Others


The launch of the emerging therapies is expected to significantly impact the Beta-Thalassemia treatment scenario in the upcoming years:-

Some of Beta-Thalassemia Drugs Covered:

  • LentiGlobin BB305
  • PTG-300
  • ACE-011 (Sotatercept)
  • Mitapivat
  • VIT 2763
  • OTL-300
  • ST-400
  • CTX001
  • DST-0509
  • ATIR201
  • Ruxolitinib
  • EDIT-301
  • And Many Others


Know more about the collaborations, tie-ups, and therapies launch @ Beta-Thalassemia Pipeline Therapies and Forecast 


Table of Contents:


Key Insights


Executive Summary of Beta-thalassemia


SWOT Analysis for Beta-Thalassemia


Beta-Thalassemia Market Overview at a Glance


Disease Background and Overview


Beta-Thalassemia Epidemiology and Patient Population


Country-Wise Beta-Thalassemia Epidemiology


Beta-Thalassemia Treatment and Management


Case Study


Beta-Thalassemia Market Unmet Needs


Beta-Thalassemia Marketed Products


Beta-Thalassemia Emerging Therapies


Beta-Thalassemia Promising Candidates


Beta-Thalassemia Therapies in the News


Beta-Thalassemia Discontinued Therapies


Beta-Thalassemia: Six Major Market Analysis


Beta-Thalassemia Market Outlook by Country


Beta-Thalassemia Market Access and Reimbursement Landscape


Beta-Thalassemia Market Drivers


Beta-Thalassemia Market Barriers




DelveInsight Capabilities




About DelveInsight


Get in touch with our Business Executive @ Beta-Thalassemia Market Outlook in the Next Decade


DelveInsght’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.   


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States